THE PEBBLES STUDY: A randomised controlled trial to prevent eczema, food allergy and sensitisation using a skin barrier improvement strategy
University of Melbourne
National Health and Medical Research Council (NHMRC)
We are aiming to find out if infant skin management with a particular cream, called EpiCeram™, might help reduce the chances that a child will develop allergies.
Eczema is often the first sign that an infant has allergies, and infants with eczema often go on to develop food allergies and other allergic diseases and asthma. It is likely that eczema allows substances from the environment (allergens) to be exposed to the immune system through the damaged skin, resulting in allergies (sensitisation). EpiCeram™ is a cream that has been designed to help build up the skin’s ability to be a barrier against the environment. This treatment contains the major components of human skin at physiological concentration. Our study intends to find out if building and maintaining infants’ skin barrier function can prevent eczema and food allergies and eventually asthma.
0-3 week old infants with family history allergy. Specifically, either one or both of the baby’s biological parents and/or siblings must suffer from any of the following conditions; asthma, eczema/atopic dermatitis, hayfever/allergic rhinitis or food allergy.
Recruitment ongoing, through March 2021.
Study contact: [email protected]
Study website: www.mspgh.unimelb.edu.au/visit/pebblesstudy
Australia New Zealand Clinical Trials Registry: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12617001380381p